table, td, td p, span, font {font-family: Arial, Helvetica, sans-serif ; font-size:11pt ;}
HEALWELL achieved revenue from continuing operations of $32.6 million in Q3-2026, an increase of 7% compared to revenue of $30.4 million in Q3-2025.
HEALWELL reported positive Adjusted EBITDA1 of $1.6 million in Q3-2026, an increase of 144% compared to Adjusted EBITDA of $0.7 million in Q3-2025. The improvement in Adjusted EBITDA margin reflects improved performance across HEALWELL’s operating segments and a 7% reduction in total operating expenses. Net loss from continuing operations, was $16.0 million in Q3-2026, unchanged from $16.0 million in Q3-2025.
Cash flow generated from operating activities was $5.9 million for the nine months ended September 30, 2026, compared to cash used of $20.1 million in the prior-year period, representing an improvement of $26.0 million, reflecting operating efficiencies realized across the organization.
On September 1, HEALWELL announced its subsidiary, Orion Health, had entered into a multi-million-dollar, multi-year agreement with Converge Health Iowa to deploy DARWEN
Toronto, Ontario–(Newsfile Corp. – November 9, 2026) – HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) (“HEALWELL” or the “Company”), a healthcare artificial intelligence company focused on preventative care, is pleased to announce its unaudited interim condensed consolidated financial results for the quarter and nine months ended September 30, 2026. A summary of the Company’s financial and operational results is set out below, and more detailed information is contained in the interim financial statements and related management discussion and analysis, which are available on the Company’s SEDAR+ page at www.sedarplus.ca. Financial measures described as “Adjusted” or “EBITDA” in this news release are non-IFRS financial measures and may not be comparable to other similar measures disclosed by other companies. Please see Non-IFRS Financial Measures below for more information.
James Lee, Chief Executive Officer of HEALWELL, commented, “The third quarter demonstrated the commercial model we have been building since the Orion Health acquisition. Our agreement with Converge Health Iowa expands an existing Orion Health infrastructure relationship into DARWEN
Anthony Lam, Chief Financial Officer of HEALWELL, commented, “Our third quarter results reflect the progress we are making in driving operational efficiencies, improving margins, and transitioning toward larger, recurring enterprise opportunities. During the first nine months of 2026, we generated $5.9 million in cash flow from operating activities, representing a $26.0 million improvement over the prior-year period, while remaining in compliance with all covenants under our credit facilities. With $14.9 million in cash and cash equivalents and a $17.7 million short-term investment representing our indirect interest in SpaceX, we believe we are well-positioned to maintain financial flexibility as we continue to focus on disciplined capital allocation and achieving sustained profitability.”
Third Quarter 2026 Financial Highlights
Significant financial highlights for the Company’s continuing operations during the three months ended September 30, 2026 included:
HEALWELL achieved quarterly revenue from continuing operations of $32.6 million in Q3-2026, an increase of 7% compared to revenue of $30.4 million generated in Q3-2025.
HEALWELL achieved Gross Profit of $17.1 million during Q3-2026, an increase of 3% compared to $16.5 million in Q3-2025.
HEALWELL achieved a Gross Margin percentage of 52% during Q3-2026, compared to 54% in Q3-2025.
During Q3-2026, HEALWELL reported positive Adjusted EBITDA¹ of $1.6 millionin Q3-2026, an increase of 144% compared to Adjusted EBITDA of $0.7 million in Q3-2025.
During Q3-2026, the Company’s IFRS net loss from continuing operations was $16.0 million, compared to a net loss of $16.0 million for the previous year, as a $2.3 million improvement in loss from operations was offset primarily by higher non-cash charges for changes in the fair value of contingent consideration, investments and options.
As of September 30, 2026, HEALWELL had $14.9 million in cash, compared to $18.6 million as of December 31, 2025.
Data Science & AI segment revenue was $1.5 million in Q3-2026 compared to $2.0 million in Q3-2025, reflecting lower project-based life sciences revenue. During 2026, HEALWELL has focused on productizing its DARWEN
Third Quarter 2026 Business and Operational Highlights
Significant business and operational highlights for the Company during the three months ended September 30, 2026 included:
International Prix Galien Nomination: On August 19, 2026, HEALWELL announced that its subsidiary Pentavere Research Group (now HEALWELL DARWEN Inc.), developer of DARWEN
Statewide U.S. HIE AI Deployment: On September 1, 2026, HEALWELL, through its subsidiary Orion Health, announced an agreement with Converge Health Iowa, Iowa’s designated statewide Health Information Exchange (“HIE”) and an existing Orion Health customer, to deploy DARWEN
WELLTRUST
Benchmark Performance: On September 15, 2026, HEALWELL announced new peer-reviewed research in which DARWEN
SMART Summary Deployment in New Brunswick: On September 23, 2026, HEALWELL announced the deployment of DARWEN
SpaceX Investment: As of September 30, 2026, the fair value of the Company’s indirect interest in SpaceX was $17.7 million, based on their market price and exchange rates in effect on that date, as compared to a carrying value of approximately CAD$4.6 million reflected in the Company’s financial statements as of March 31, 2026. HEALWELL acquired its indirect interest in SpaceX through its prior investment in xAI Corp. in May 2024, which was acquired by SpaceX in February 2026. The investment continues to be held indirectly through a private fund and is subject to customary lock-up restrictions which are expected to fully expire in February 2027. Management expects to realize the investment within twelve months through a distribution, with the proceeds intended to strengthen HEALWELL’s balance sheet and liquidity position.
Events Subsequent to September 30, 2026
Significant business and operational highlights for the Company subsequent to September 30, 2026 included:
Peer-Reviewed MyHealthNB Research and DARWEN
TIME Recognition and Fall Research Program: On October 15, 2026, HEALWELL announced that it had been named to TIME’s World’s Top HealthTech Companies of 2026 in the AI & Data Analytics category, and that HEALWELL and its collaborators are presenting 12 scientific abstracts and presentations at 8 international conferences this fall.
Webcast and Conference Call Details
HEALWELL will be holding a conference call and simultaneous webcast to discuss its financial results on Tuesday, November 10, 2026 at 8:30 am EST (6:30 am PCT). The call will be hosted by James Lee, Chief Executive Officer, Dr. Alexander Dobranowski, President, and Anthony Lam, Chief Financial Officer. Please dial-in 10 minutes prior to the start of the call.
Time: 8:30 AM EST / 6:30 AM PCT
Webcast link: https://bit.ly/AIDX-Q3
Toll-Free North America: (+1) 800 431 2204
Toronto Local and International Toll: (+1) 289 514 5015
When connecting to the conference call via phone, please dial in 10 minutes prior to the start of the call and ask to be joined into the “HEALWELL AI Inc. Conference Call.”
Selected Financial Information
(in thousands of Canadian dollars, except percentages and per share amounts)
| Three months ended | Period-Over-Period Change | Nine months ended | Period-Over-Period Change | |||||||||||||||||||||
| September 30, | September 30, | |||||||||||||||||||||||
| 2026 | 2025 | $ | % | 2026 | 2025 | $ | % | |||||||||||||||||
| Revenue | 32,582 | 30,354 | 2,228 | 7% | 98,746 | 71,587 | 27,159 | 38% | ||||||||||||||||
| Cost of Sales | 15,516 | 13,844 | 1,672 | 12% | 44,255 | 31,940 | 12,315 | 39% | ||||||||||||||||
| Gross Profit | 17,066 | 16,510 | 556 | 3% | 54,491 | 39,647 | 14,844 | 37% | ||||||||||||||||
| Operating Expenses | ||||||||||||||||||||||||
| General and administrative | 7,745 | 8,187 | (442 | ) | (5)% | 25,958 | 23,049 | 2,909 | 13% | |||||||||||||||
| Research and development | 4,557 | 4,892 | (335 | ) | (7)% | 15,440 | 12,121 | 3,319 | 27% | |||||||||||||||
| Sales and marketing | 2,820 | 2,386 | 434 | 18% | 8,949 | 5,822 | 3,127 | 54% | ||||||||||||||||
| Share-based payments | 2,950 | 3,148 | (198 | ) | (6)% | 7,040 | 10,169 | (3,129 | ) | (31)% | ||||||||||||||
| Amortization of intangible assets | 4,474 | 5,565 | (1,091 | ) | (20)% | 12,946 | 12,863 | 83 | 1% | |||||||||||||||
| Depreciation of property and equipment | 157 | 192 | (35 | ) | (18)% | 326 | 465 | (139 | ) | (30)% | ||||||||||||||
| Depreciation of ROU assets | 638 | 732 | (94 | ) | (13)% | 2,099 | 1,276 | 823 | 64% | |||||||||||||||
| Total Operating Expenses | 23,341 | 25,102 | (1,761 | ) | (7)% | 72,758 | 65,765 | 6,993 | 11% | |||||||||||||||
| Loss from Operations | (6,275 | ) | (8,592 | ) | 2,317 | 27% | (18,267 | ) | (26,118 | ) | 7,851 | 30% | ||||||||||||
| Other Income and Expenses | ||||||||||||||||||||||||
| Financing expenses | 3,217 | 3,769 | (552 | ) | (15)% | 9,376 | 6,750 | 2,626 | 39% | |||||||||||||||
| Effect of foreign exchange rate | 12 | 1,927 | (1,915 | ) | (99)% | (43 | ) | 644 | (687 | ) | (107)% | |||||||||||||
| Changes in FMV of Contingent Consideration, Investments and Options | 5,048 | 1,116 | 3,932 | 352% | (11,985 | ) | 2,757 | (14,742 | ) | (535)% | ||||||||||||||
| Changes in FV of derivative liability | 614 | 488 | 126 | 26% | (1,065 | ) | (2,838 | ) | 1,773 | 62% | ||||||||||||||
| Current and Deferred Taxes | 873 | 106 | 767 | 724% | 1,939 | (1,062 | ) | 3,001 | 283% | |||||||||||||||
| Net loss from continuing operations | (16,039 | ) | (15,998 | ) | (41 | ) | -% | (16,489 | ) | (32,369 | ) | 15,880 | 49% | |||||||||||
| Net loss from discontinued operations | 139 | (12,011 | ) | 12,150 | 101% | 139 | (13,803 | ) | 13,942 | 101% | ||||||||||||||
| Net loss for the period | (15,900 | ) | (28,009 | ) | 12,109 | 43% | (16,350 | ) | (46,172 | ) | 29,822 | 65% | ||||||||||||
| EBITDA[1][2] | (7,384 | ) | (6,366 | ) | (1,018 | ) | (16)% | 7,866 | (13,353 | ) | 21,219 | 159% | ||||||||||||
| ADJUSTED EBITDA1 | 1,646 | 675 | 971 | 144% | 3,518 | 892 | 2,626 | 294% | ||||||||||||||||
| Subscription, Support and Maintenance Revenue | 22,837 | 21,014 | 1,823 | 9% | 66,239 | 45,699 | 20,540 | 45% | ||||||||||||||||
[1] EBITDA and Adjusted EBITDA are non-IFRS financial measures and do not have any standardized meaning under IFRS Accounting Standards. These measures may not be comparable to similar measures used by other issuers. See “Non-IFRS Measures”.
[2] EBITDA and Adjusted EBITDA are non-IFRS financial measures and do not have any standardized meaning under IFRS Accounting Standards. These measures may not be comparable to similar measures used by other issuers. See “Non-IFRS Measures”.
Segmented Revenue
| Healthcare Software | Three months ended September 30, | Period-Over-Period Change | Nine months ended September 30, | Period-Over-Period Change | ||||||||||||||||||||
| 2026 | 2025 | $ | % | 2026 | 2025 | $ | % | |||||||||||||||||
| Subscription, Support and Maintenance | 22,379 | 20,330 | 2,049 | 10% | 64,790 | 44,093 | 20,697 | 47% | ||||||||||||||||
| Professional Services | 8,551 | 7,925 | 626 | 8% | 27,125 | 19,402 | 7,723 | 40% | ||||||||||||||||
| Software License | 108 | 126 | (18 | ) | (14)% | 709 | 1,037 | (328 | ) | (32)% | ||||||||||||||
| Total Revenue | 31,038 | 28,381 | 2,657 | 9% | 92,624 | 64,532 | 28,092 | 44% | ||||||||||||||||
| Data Science & AI | Three months ended September 30, | Period-Over-Period Change | Nine months ended September 30, | Period-Over-Period Change | ||||||||||||||||||||
| 2026 | 2025 | $ | % | 2026 | 2025 | $ | % | |||||||||||||||||
| Subscription, Support and Maintenance | 458 | 684 | (226 | ) | (33)% | 1,449 | 1,606 | (157 | ) | (10)% | ||||||||||||||
| Professional Services | 1,086 | 1,289 | (203 | ) | (16)% | 4,673 | 5,449 | (776 | ) | (14)% | ||||||||||||||
| Software License | – | – | – | 0% | – | – | – | 0% | ||||||||||||||||
| Total Revenue | 1,544 | 1,973 | (429 | ) | (22)% | 6,122 | 7,055 | (933 | ) | (13)% | ||||||||||||||
Non-IFRS Financial Measures
The terms EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin used in this document do not have any standardized meaning under IFRS, may not be comparable to similar financial measures disclosed by other companies and should not be considered a substitute for, or superior to, IFRS financial measures. Readers are advised to review the section entitled “Non-IFRS Financial Measures” in the Company’s management discussion and analysis for the quarter ended September 30, 2026, available on the Company’s SEDAR+ page at www.sedarplus.ca, for a detailed explanation of the composition of these measures and their uses.
The following table reconciles EBITDA and Adjusted EBITDA to net loss from continuing operations for the three and nine months ended September 30, 2026 and September 30, 2025:
| Three months ended | Nine months ended | |||||||||||
| September 30, | September 30, | September 30, | September 30, | |||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||
| Net loss | (16,039 | ) | (15,998 | ) | (16,489 | ) | (32,369 | ) | ||||
| Add: Financing expenses | 3,217 | 3,769 | 9,376 | 6,750 | ||||||||
| Add: Depreciation of property equipment | 157 | 192 | 326 | 465 | ||||||||
| Add: Amortization of intangible assets | 4,474 | 5,565 | 12,946 | 12,863 | ||||||||
| Less: Lease interest and bank charges retained in EBITDA | (66 | ) | – | (232 | ) | – | ||||||
| Add: Current and deferred taxes | 873 | 106 | 1,939 | (1,062 | ) | |||||||
| EBITDA | (7,384 | ) | (6,366 | ) | 7,866 | (13,353 | ) | |||||
| Add: Restructuring and Integration cost | 109 | 54 | 1,042 | 532 | ||||||||
| Add: Effect of foreign exchange rate | 12 | 1,927 | (43 | ) | 644 | |||||||
| Add: Changes in FMV of Contingent Consideration, Investments Options | 5,048 | 1,116 | (11,985 | ) | 2,757 | |||||||
| Add: Stock compensation | 2,950 | 3,148 | 7,040 | 10,169 | ||||||||
| Add: Acquisition related expenses | 297 | 308 | 663 | 2,981 | ||||||||
| Less: Changes in FV of derivative liability | 614 | 488 | (1,065 | ) | (2,838 | ) | ||||||
| Adjusted EBITDA | 1,646 | 675 | 3,518 | 892 | ||||||||
1 EBITDA, Adjusted EBITDA and Adjusted EBITDA Margin are non-IFRS financial measures. See “Non-IFRS Financial Measures” above.
James Lee
Chief Executive Officer
HEALWELL AI Inc.
About HEALWELL AI
HEALWELL AI is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve health outcomes with better care and technology. HEALWELL is executing its strategy by developing and acquiring technology and clinical science capabilities that complement its business of preventative care, including data science, AI-powered patient identification, and clinical decision support. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol “AIDX” and on the OTC Exchange under the symbol “HWAIF”. Learn more at www.healwell.ai.
Forward-Looking Statements
Certain statements in this press release, constitute “forward-looking information” and “forward looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities laws, including statements about the expected benefits of, and recurring revenue to be generated over the term of, the Company’s agreement with Converge Health Iowa; the Company’s ability to cross-sell its AI solutions across Orion Health’s customer base; the expected expiry of lock-up restrictions on the Company’s indirect interest in SpaceX common shares and the future value of that investment; the continued deployment of the Company’s SMART Suite and the continued growth of the WELLTRUST
Known and unknown risk factors, many of which are beyond the control of HEALWELL, could cause the actual results of HEALWELL to differ materially from the results, performance, achievements, or developments expressed or implied by such forward-looking statements. Such risk factors include but are not limited to those factors which are discussed under the section entitled “Risk Factors” in HEALWELL’s most recent annual information form dated March 18, 2026, which is available under HEALWELL’s SEDAR+ profile at www.sedarplus.ca. The risk factors are not intended to represent a complete list of the factors that could affect HEALWELL and the reader is cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking statements. There can be no assurance that forward looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Forward-looking statements are provided for the purpose of providing information about management’s expectations and plans relating to the future. HEALWELL disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, or to explain any material difference between subsequent actual events and such forward-looking statements, except to the extent required by applicable law. All of the forward-looking statements contained in this press release are qualified by these cautionary statements.
For more information:
Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
ir@healwell.ai
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/323259
View more news from HEALWELL AI
You are receiving this email because you have previously indicated your interest in receiving news for HEALWELL AI
If you no longer want to receive messages from us, you can click here to unsubscribe.
Anti-Spam Policy | Privacy Policy
The post HEALWELL More than Doubles YoY Adjusted EBITDA in Q3-2026 and Improves YTD Operating Cashflow by $26 Million first appeared on PressReleaseCC.
HEALWELL More than Doubles YoY Adjusted EBITDA in Q3-2026 and Improves YTD Operating Cashflow by $26 Million first appeared on Web and IT News.
At just 1.8cm thick and lighter than a smartphone, EYERZ’s UL-certified rechargeable hand warmer combines…
Google announced its latest AI model, Gemini 4 Hydrogen, aimed at bringing “cutting-edge intelligence to…
Updated 6:20 a.m. ET Friday: Microsoft reported more progress as the business day got underway…
While the tech world is still reeling from Jensen Huang’s resignation as Nvidia CEO, at…
Nvidia named finance chief Colette Kress interim CEO on Thursday after Jensen Huang resigned as…
A quantum computer big enough to do useful work will need a great deal of…
This website uses cookies.